Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study

Cancer Communications

Table 4 Subset analyses on tumor control in patients with locoregionally advanced NPC treated by NAC plus IMRT vs. CCRT plus AC

Stage	OS		LRRFS		DMFS		DFS
Stage	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Overall	1.14 (0.70–1.87)	0.599	1.27 (0.62–2.59)	0.515	1.22 (0.72–2.08)	0.456	1.16 (0.74–1.81)	0.517
III	1.52 (0.68–3.39)	0.308	2.23 (0.79–6.24)	0.119	1.62 (0.69–3.80)	0.259	1.62 (0.83–3.16)	0.155
IV	1.04 (0.55–1.96)	0.912	0.65 (0.21–1.98)	0.440	1.11 (0.55–2.21)	0.777	0.92 (0.50–1.70)	0.789
T1–2	0.70 (0.14–3.48)	0.663	50.52 (0–6.22 × 10⁸)	0.386	0.48 (0.11–2.17)	0.332	0.65 (0.16–2.60)	0.537
T3–4	1.23 (0.73–2.07)	0.430	1.25 (0.61–2.57)	0.548	1.41 (0.80–2.49)	0.237	1.27 (0.79–2.02)	0.325
N0–1	1.17 (0.60–2.28)	0.638	1.38 (0.55–3.47)	0.487	1.12 (0.54–2.32)	0.766	1.08 (0.60–1.94)	0.797
N2–3	1.11 (0.52–2.37)	0.783	1.01 (0.31–3.30)	0.990	1.42 (0.66–3.07)	0.370	1.27 (0.64–2.52)	0.487

OS overall survival, LRRFS locoregional relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival, HR hazard ratio, CI confidence interval. Other abbreviations as in Table 1